



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/758,683	01/14/2004	Jeannette Whitcomb	11068-078-999	4994
7590		11/28/2007	EXAMINER	
JONES DAY		PARKIN, JEFFREY S		
222 East 41st Street		ART UNIT		
New York, NY 10017		PAPER NUMBER		
		1648		
		MAIL DATE		
		DELIVERY MODE		
		11/28/2007		
		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

# Office Action Summary

Application No.

10/758,683

Applicant(s)

WHITCOMB, JEANNETTE

Examiner

Jeffrey S. Parkin, Ph.D.

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2007.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 83-89 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 83-89 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

Serial No.: 10/758,683  
Applicant: Whitcomb, J.

Docket No.: 11068-078-999  
Filing Date: 01/14/2004

### **Detailed Office Action**

#### **Status of the Claims**

Acknowledgement is hereby made of receipt and entry of the communication filed 12 September, 2007. Claims 83-89 are pending in the instant application.

#### **35 U.S.C. § 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

The previous rejection of claims 83-85 and 89 under 35 U.S.C. § 102(a) as being clearly anticipated by Fujiwara et al. (1998), is hereby withdrawn in response to applicant's amendment.

#### **35 U.S.C. § 112, First Paragraph**

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

**Scope of Enablement**

Claims 83-89 are rejected under 35 U.S.C. § 112, first paragraph, because the specification does not reasonably enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The claims are directed toward a method for assessing the effectiveness of an NNRTI on an HIV-infected patient comprising evaluating nucleic acid samples obtained from patient plasma for certain mutations in the RT. Appropriately drafted claim language directed toward HIV-1-infected patients and the specific mutations identified in the specification would be appropriate (see **Allowable Subject Matter** below for suggested claim language).

The legal considerations that govern enablement determinations pertaining to undue experimentation have been clearly set forth. *Enzo Biochem, Inc.*, 52 U.S.P.Q.2d 1129 (C.A.F.C. 1999). *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988). *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that several factual inquiries should be considered when making such assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

The disclosure fails to provide adequate guidance pertaining to the genotypic/phenotypic properties of other RTs as it pertains to NNRTI increased/decreased susceptibility. The NNRTIs interact in a highly specific manner with the RT based upon steric constraints. Thus, only a limited number of amino acid mutations are permitted that lead to the desired phenotype. Thus, the skilled artisan would readily question the ability of other mutations at the disclosed location to produce a mutant RT with the desired phenotype.

The disclosure fails to provide sufficient guidance pertaining to the presence of the claimed mutations in the human immunodeficiency virus type 2 (HIV-2) RT. Although HIV-1 and -2 are both lentiviruses, they only display ~35-38% genetic relatedness at the nucleotide sequence level. Accordingly, considering the genetic unrelatedness between these two viruses, it seems improbable that the same mutations in HIV-1 RT would be present in the HIV-2 RT.

The prior art teaches that a limited number of substitutions are associated with increased/decreased NNRTI drug resistance (Fujiwara et al., 1998; Bacheler et al., 2001; Ceccherini-Silberstein et al., 2007). However, the claims are broadly directed toward any combination of amino acid substitutions. This constitutes a rather large genus of variants which are not supported by the disclosure. For instance, would the skilled artisan reasonably expect G190W and K101H to display increased/decreased susceptibility to NNRTIs?

Accordingly, when all the aforementioned factors are considered in toto, it would clearly require undue experimentation to practice the claimed invention in a manner commensurate in scope with the claims.

**Allowable Subject Matter**

As previously set forth, it appears that the combination of mutations G190A/S, K101E, and A98G are free of the prior art. Appropriately drafted claim language directed toward these combinations of mutations would be allowable (i.e., A method of assessing the effectiveness of a nonnucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient, comprising evaluating whether a plasma sample collected from the HIV-1-infected patient comprises a encoding a reverse transcriptase (RT) that has one of the following mutations: G190A/S and K101E; G190A/S, K101E, and K103N; G190A/S and A98G; (etc.), wherein said mutation is associated with an increased susceptibility to...).

**Correspondence**


Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the

Updated Notice of Centralized Delivery and Facsimile  
Transmission Policy for Patent Related Correspondence, and  
Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29,  
2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,



Jeffrey S. Parkin, Ph.D.  
Primary Examiner  
Art Unit 1648

26 November, 2007